Jagsonpal Pharmaceuticals Analysis

dividend

Pros

• Dividends paid are thoroughly covered by earnings (14.2x coverage).
• Jagsonpal Pharmaceuticals's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).

Cons

• No dividend growth in 10 years.
• Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
• Jagsonpal Pharmaceuticals's dividend is below the markets top 25% of dividend payers in India (3.08%).

health

Pros

• Jagsonpal Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
• Jagsonpal Pharmaceuticals is profitable, therefore cash runway is not a concern.
• Jagsonpal Pharmaceuticals is profitable, therefore cash runway is not a concern.
• Debt is well covered by operating cash flow (688.2%, greater than 20% of total debt).
• Debt is covered by short term assets, assets are 23.3x debt.
• Jagsonpal Pharmaceuticals's cash and other short term assets cover its long term commitments.
• The level of debt compared to net worth has been reduced over the past 5 years (36.1% vs 4.1% today).
• Jagsonpal Pharmaceuticals earns more interest than it pays, coverage of interest payments is not a concern.
• Jagsonpal Pharmaceuticals's level of debt (4.1%) compared to net worth is satisfactory (less than 40%).

Cons

• High level of physical assets or inventory.

management

Pros

• The tenure for the Jagsonpal Pharmaceuticals board of directors is about average.
• Rajpal P.'s remuneration is lower than average for companies of similar size in India.
• Rajpal P.'s compensation has been consistent with company performance over the past year, both up more than 20%.
• The average tenure for the Jagsonpal Pharmaceuticals management team is over 5 years, this suggests they are a seasoned and experienced team.

Cons

misc

Pros

Cons

• Jagsonpal Pharmaceuticals is not covered by any analysts.
• Jagsonpal Pharmaceuticals has significant price volatility in the past 3 months.

past

Pros

• Jagsonpal Pharmaceuticals's 1-year earnings growth exceeds its 5-year average (212.6% vs 8.5%)
• Jagsonpal Pharmaceuticals's year on year earnings growth rate has been positive over the past 5 years.
• Jagsonpal Pharmaceuticals has improved its use of capital last year versus 3 years ago (Return on Capital Employed).
• Jagsonpal Pharmaceuticals's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (212.6% vs 22.7%).

Cons

• Jagsonpal Pharmaceuticals used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
• Jagsonpal Pharmaceuticals has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).

value

Pros

• Jagsonpal Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
• Jagsonpal Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).
• Jagsonpal Pharmaceuticals is good value based on assets compared to the IN Pharmaceuticals industry average.
• Jagsonpal Pharmaceuticals is good value based on earnings compared to the IN Pharmaceuticals industry average.
• Jagsonpal Pharmaceuticals is good value based on earnings compared to the India market.
• 507789 outperformed the Market in India which returned -14.5% over the past year.
• BSE:507789 is up 16.9% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
• BSE:507789 is up 16.9% outperforming the market in India which returned 8% over the past month.

Cons

• 507789 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.